Abstract:Background Loss-of-function mutations or abnormal expressions of E ubiquitin ligases contributes to tumorigenesis. TRIM38 was reported to regulate immunity, inflammatory responses or apoptosis, but its roles in tumor progression remain inconclusive. This study aimed to investigate the functional roles of TRIM38 in bladder cancer to identify effective targets. Methods Firstly, the expression data of ubiquitination-associated genes were derived from the TCGA-BLCA cohort. Univariate Cox regression method was utilized to screen prognostic genes. Colony formation assay, Transwell assay, sphere formation assays were used to assess functional roles of TRIM38. TAP/MS assay was used to identify downstream substrates of TRIM38. Fresh clinical BLCA tissues were collected to evaluate the clinicopathological features of patients with different TRIM38 expression. The subcutaneous tumor models were established to determine the drug efficacy of BAY-876. Results A list of ubiquitination-associated signature was identified based on the screening in TCGA-BLCA cohort. Subsequent validations revealed that TRIM38 was a significant suppressor in tumors, which was expressed lowly in BLCA. Kaplan–Meier analysis and correlation analysis suggested that patients with low TRIM38 expressions had shorter survival time and advanced clinical characteristics. Targeting TRIM38 reinforced BLCA cells proliferation, migration and stemness. Mechanistically, TRIM38 interacted with GLUT1, thereby promoting its ubiquitinoylation and degradation. Furthermore, TRIM38 deficiency relied on accumulated GLUT1 proteins to enhance BLCA malignant features and cellular glycolytic capacity. We accordingly investigated the efficacy of GLUT1 inhibitor (BAY-876) in BLCA and determined its IC50 values across cell lines. Tumor xenograft models further validated that BAY-876 could effectively suppress the in vivo growth of TRIM38 low/− BLCA. Conclusions Our results suggested that TRIM38 plays a tumor suppressive role in BLCA pathogenesis and TRIM38/GLUT1 axis is a therapeutic vulnerability for clinical treatment, which possessing great translational significance.

TRIM37 promotes gallbladder cancer proliferation by activating the Wnt/β-catenin pathway via ubiquitination of Axin1

TRIM47 is a Prognostic Biomarker for Gallbladder Cancer and Promotes Tumor Progression Through Regulating K63-linked Ubiquitination of PARP1

The E3 Ubiquitin Ligase TRIM11 Facilitates Gastric Cancer Progression by Activating the Wnt/β-Catenin Pathway via Destabilizing Axin1 Protein

TRIM24 promotes the aggression of gastric cancer via the Wnt/β-catenin signaling pathway.

The E3 ubiquitin ligase TRIM17 promotes gastric cancer survival and progression via controlling BAX stability and antagonizing apoptosis

TRIM37 promoted the growth and migration of the pancreatic cancer cells

TRIM47 drives gastric cancer cell proliferation and invasion by regulating CYLD protein stability

Over-expression of TRIM37 promotes cell migration and metastasis in hepatocellular carcinoma by activating Wnt/β-catenin signaling.

Knockdown of TRIM37 Promotes Apoptosis and Suppresses Tumor Growth in Gastric Cancer by Inactivation of the ERK1/2 Pathway.

TRIM50 Inhibits Proliferation and Metastasis of Gastric Cancer via Promoting β-Catenin Degradation

TRIM38 Triggers the Uniquitination and Degradation of Glucose Transporter Type 1 (GLUT1) to Restrict Tumor Progression in Bladder Cancer

TRIM29 Overexpression is Associated with Poor Prognosis and Promotes Tumor Progression by Activating Wnt/β-catenin Pathway in Cervical Cancer.

TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance

TRIM29 facilitates the epithelial-to-mesenchymal transition and the progression of colorectal cancer via the activation of the Wnt/β-catenin signaling pathway

TRIM21-mediated Ubiquitylation of TAT Suppresses Liver Metastasis in Gallbladder Cancer

Knockdown of Tripartite Motif-Containing Protein 37 (trim37) Inhibits the Proliferation and Tumorigenesis in Colorectal Cancer Cells

TRIM37 Promotes Pancreatic Cancer Progression through Modulation of Cell Growth, Migration, Invasion, and Tumor Immune Microenvironment

Targeting TRIM54/Axin1/β-Catenin Axis Prohibits Proliferation and Metastasis in Hepatocellular Carcinoma

Downregulation of TRIM27 Suppresses Gastric Cancer Cell Proliferation Via Inhibition of the Hippo-BIRC5 Pathway.

Tripartite Motif Containing 66 Promotes Malignant Progression of Bladder Cancer by Activating Matrix Metallopeptidase 11

Tripartite Motif‐containing 37 (TRIM37) Promotes the Aggressiveness of Non‐small‐cell Lung Cancer Cells by Activating the NF‐κB Pathway